A clinical trial conducted at UNC Lineberger Comprehensive Cancer Center and Johns Hopkins Sidney Kimmel Comprehensive Cancer Center found that high-dose cytarabine followed by subsequent immunotherapy […]
For the first time, the IASLC’s Staging and Prognostic Factors Committee (SPFC) has accumulated molecular biomarker data to complement Tumor, Node, and Metastasis (TNM)-based prognostication. Results from the […]
A study presented today at the IASLC 2021 World Conference on Lung Cancer suggests how oncology practices in the United States changed after 2018, when durvalumab became available for […]
For men with “low-risk” prostate cancer initially managed with active surveillance, cancer-related factors such as tumor grade and size are key risk factors for conversion to active […]